Patient-Centered Approaches to Treatment of Migraine: Real-World Cases with Real-World Challenges

Please Log In or Register to continue.

Release Date: February 20, 2015
Expiration Date: February 20, 2016

Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

This accredited activity will provide participants with critical information and recommendations concerning current, new and emerging therapeutic strategies in episodic migraine, and best practices for integrating new treatments into existing clinical strategies, exemplified by case presentations of real-world, challenging patients with migraine. This educational activity will provide learners with the knowledge and understanding required to assess all possible therapeutic strategies for their patients who experience this headache disorder.

Target Audience

This activity is designed for physicians, nurses, and other health care professionals who have an interest in enhancing their clinical skills in treatment of migraine.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize guidelines and evidence-based therapeutic strategies in the diagnosis, assessment, and treatment selection process for patients who present with migraine-like symptoms
  • Differentiate strategies for selecting and sequencing treatments for migraine, focusing on the potential benefits and drawbacks of each
  • Compare and contrast potential side effects of therapeutic strategies for episodic migraine, focusing on proactive strategies designed to minimize negative impact on continuation of therapy and patient compliance
  • Identify potential barriers to treatment, and employ appropriate patient-centered approaches to the management of individuals with episodic migraine


Welcome and Introductions – Roger K. Cady, MD

Current Practice Management in Migraine: When, Why and How? – Susan L. Hutchinson, MD

New and Emerging Therapeutic Strategies in Migraine – Roger K. Cady, MD

Patient-Centered Approaches to Migraine – Roger K. Cady, MD and Susan L. Hutchinson, MD

Summary and Conclusion, Questions and Answers

Instructions for Participation and Credit

This activity is eligible for credit through February 20, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Roger K. Cady, MD
CEO, Banyan Group, Inc.
Director, Headache Care Center
Founder, Clinvest Research and Primary Care Network
Springfield, Missouri

Dr. Roger Cady received his medical degree from the Hormel Institute, University of Minnesota Mayo Medical School in Rochester, Minnesota. He completed his residency in family practice at St. Francis-Mayo Family Practice in LaCrosse, Wisconsin. Dr. Cady is CEO of Banyan Group, Inc. and director of the Headache Care Center, as well as founder of Clinvest Research and Primary Care Network, all located in Springfield, Missouri.

Dr. Cady holds memberships in the American Academy of Family Physicians, American Academy of Pain Management, International Headache Society, American Academy of Pain Medicine, American Headache Society, National Headache Foundation, American Society for Clinical Pharmacology and Therapeutics, and the Missouri State Medical Association, among others. He is president of the National Board for Certification in Headache Management, vice president of National Headache Foundation, and is on the advisory board of Allergan, MAP Pharmaceuticals, Merck & Co., NuPathe Pharmaceuticals, Ortho-McNeil, Zogenix, Novartis, Nautilus Neuroscience, and Janssen Biotech, Inc. Dr. Cady has published more than 250 peer-reviewed journal articles.

Susan L. Hutchinson, MD
Orange County Migraine & Headache Center
Irvine, California

Dr. Susan Hutchinson received her medical degree from Medical College of Ohio, followed by her internship and residency at UC Irvine where she completed her training in the Department of Family Medicine. Dr. Hutchinson, a headache specialist and board-certified family practice physician, founded Orange County Migraine & Headache Center, dedicated to serving patients with headache and mood disorders. Prior to starting Orange County Migraine & Headache Center, she practiced as a family practice physician in the Irvine Area.

Dr. Hutchinson is very active in numerous professional organizations such as the American Headache Society and the National Headache Foundation, and is president of the Orange County Chapter of the California Academy of Family Physicians. She is the immediate post-chair of the Women's Issues section of the American Headache Society after serving in the chair position for five years. Dr. Hutchinson lectures nationally on the subject of headache, has written dozens of articles for medical journals, and participated in headache research projects.

Over the years, Dr. Hutchinson developed a passion for helping patients with headache, especially migraine. Dr. Hutchinson suffers from migraine headaches which gives her empathy with her patients. She has also developed a special interest in treating mood disorders including depression, anxiety, bipolar disorder, ADHD, and panic attacks, and she has devoted her career to alleviating the suffering caused by both headaches and mood disorders.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 15-015-002


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Roger Cady has received honoraria related to formal advisory activities from Aerocrine, Allergan, Inc., Avanir Pharmaceuticals, Inc., Boston Scientific Corporation, Depomed, Inc., Merck & Co., Inc., Novartis AG, OptiNose US Inc., Pfizer Inc., and Zogenix, Inc.; speakers’ bureau activities from Allergan, Impax Pharmaceuticals, Merck, Nautilus Neurosciences, Novartis, and Zogenix; and consultant fees from Aerocrine, Allergan, Avanir, Becker Pharmaceuticals, Duke University, Depomed, Evidera, Impax, Merck, NuPathe Inc., and Zogenix. In addition, he has received honoraria related to the development of educational materials from Managing Migraine - A Healthcare Professional's Guide to Collaborative Migraine Care, Managing Migraine - A Patient's Guide to Successful Migraine Care, and The Adherence Principle. Dr. Cady has also received grant support related to research activities from Allergan, Amgen, AstraZeneca, Boston Scientific, ElectroCore, Forest Pharmaceuticals, Inc. (a subsidiary of Forest Laboratories, Inc.), Janssen Pharmaceuticals, Inc., OptiNose, Pearl Therapeutics Inc., Tian Medical, and Zogenix.

Dr. Susan Hutchinson has received honoraria related to formal advisory activities from Avanir Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.; the development of educational materials from Allergan, Inc. and Teva; speakers’ bureau activities from Allergan, Takeda and Zogenix, Inc.; and consultant fees from Allergan.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Cady and Dr. Hutchinson have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Cady and Dr. Hutchinson have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flashreg; Player, Adobe® Acrobat®, Windows Media® Player and/or Microsoft® Silverlight.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Teva Pharmaceuticals.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.